Ajax Therapeutics is a pioneering biopharmaceutical company focused on developing next-generation JAK inhibitors for patients suffering from myeloproliferative neoplasms (MPNs). Established in 2019, Ajax is leveraging its breakthrough research combining advancements in computational drug discovery and detailed protein structure analysis to target unmet therapeutic needs in hematologic cancers.
The company's lead product, AJ1-11095, distinguishes itself as the first Type II JAK2 inhibitor to commence clinical trials, currently in a Phase I study in the US. This innovative approach has demonstrated potential to enhance therapeutic success, surpass disease persistence seen in Type I inhibitors, and diminish mutant JAK2 allele burdens, opening new avenues in treating resistant myelofibrosis (MF).
In May 2024, Ajax Therapeutics secured a substantial $95.00M Series C investment. Notable investors include RA Capital Management, Vivo Capital, Boxer Capital, EcoR1 Capital, Goldman Sachs Asset Management, Inning One Ventures, Eli Lilly & Company Foundation, Point72 Ventures, and Schrödinger.
-logo.jpg "Entero Therapeutics (Nasdaq: ENTO)"){kind=logo}